Abstract
Preclinical brain positron emission tomography (PET) in animals is performed using anesthesia to avoid movement during the PET scan. In contrast, brain PET scans in humans are typically performed in the awake subject. Anesthesia is therefore one of the principal limitations in the translation of preclinical brain PET to the clinic. This review summarizes the available literature supporting the confounding effect of anesthesia on several PET tracers for neuroscience in preclinical small animal scans. In a second part, we present the state-of-the-art methodologies to circumvent this limitation to increase the translational significance of preclinical research, with an emphasis on motion correction methods. Several motion tracking systems compatible with preclinical scanners have been developed, each one with its advantages and limitations. These systems and the novel experimental setups they can bring to preclinical brain PET research are reviewed here. While technical advances have been made in this field, and practical implementations have been demonstrated, the technique should become more readily available to research centers to allow for a wider adoption of the motion correction technique for brain research.
Introduction
Positron emission tomography (PET) is a molecular imaging technique that allows to quantify the distribution of radiolabeled biomolecules in the living body. In the clinic, PET is commonly used for diagnostic workup and treatment monitoring in fields like oncology, neurology, or cardiology (–). In addition, PET is a valuable tool for clinical as well as fundamental research in these fields as it allows to investigate molecular mechanisms of several diseases or drugs and their efficacy.
Preclinical PET, commonly performed in non-human primates and rodents to help development and validation of novel radiotracers, investigate molecular mechanisms of disease in animal models, test drug safety, efficacy, and response to treatments. In contrast to PET in humans, animal scans are usually performed using anesthesia to maintain the animal still during the scan. Propofol, ketamine, and isoflurane are some of the most common anesthetics used for animal immobilization in preclinical PET (). Unfortunately these compounds can have a pharmacological effect, affecting physiological parameters such as body temperature and cerebral blood flow, which in turn can affect the pharmacokinetics of a radiotracer (). In addition, these anesthetics have been proven to work principally by interaction with neurotransmitter systems (), which, for many neurological studies, are in fact the object of study. Because of these effects, the use of anesthesia in preclinical brain PET studies can be considered a confounding factor, and one of the principal limitations for translation of preclinical results to the clinic ().
Several studies have investigated the effect of anesthesia on preclinical brain PET for many different anesthetics and tracers in the context of brain PET imaging. In the following sections these studies are summarized. In the second part we discuss motion correction solutions to circumvent the use of anesthesia in preclinical brain PET. Motion correction techniques offer the advantage of being potentially adaptable to common preclinical PET scanners, as well as allowing free animal motion.
Anesthesia as a Confounding Factor in Preclinical Pet Studies
The first use of anesthetics dates back to the nineteenth century (), however, despite being used for more than 100 years, it is only since the last decades that research on their molecular mechanisms of action has been possible thanks to the development of advanced techniques. Nonetheless, fundamental aspects of their mechanisms of action still need to be elucidated ().
Molecular Effects of General Anesthesia
Several hypotheses on the mechanisms of action of anesthetic agents have been formulated from the observation that the potency of anesthetic agents increased in proportion to its solubility in lipids. These theories stipulated that anesthetic agents changed the properties of the membrane lipid bilayer, such as its permeability, fluidity, and dimensions (). Many of these theories were proved inconsistent with experimental results and were discarded. Although the focus has been shifted to the interaction of anesthetics with voltage and ligand gated ion-channels (see below), recent research has pointed again to the interaction of anesthetics with the cellular membrane, but instead of acting on the membrane bulk, it has been suggested that the interaction occurs at membrane rafts (). Rafts are regions of ordered lipids (e.g., cholesterol, sphingolipids, and phospholipids) in the membrane, which in contrast to the more fluid bulk of the bilayer, are more rigid (). Several ion channels associate with membrane drafts and it is believed that the interaction with these rafts can regulate the channel physiology (). In a study by Pavel et al. (), it is shown that anesthesia (e.g., chloroform and isoflurane) induced disruption of membrane rafts associated with the 2-pore domain K+ channel TREK-1, a mechano-, and thermo-sensitive K+ channel. This disruption activates this channel, which in turn affects anesthesia potency. This theory was further validated using TREK-1 knock-out mice. These mice displayed more resistance to anesthetics compared to control animals as measured by the onset time of anesthesia action, the loss of righting reflex, and the inspired minimum alveolar anesthetic concentration (, ).
As mentioned above, other mechanisms of action involve the direct interaction of anesthetics with voltage-gated and ligand-gated ion channels, the latter being the most frequent case (, ). For example, the anesthetic ketamine is an antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor, inhibiting glutamate binding to the receptor. However, it is not clear if blocking of the NMDA receptor is the main mechanism of action of anesthetics targeting this receptor (). Using dizocilpine (MK 801), a more potent NMDA receptor antagonist than ketamine, no hypnotic effect is observed, suggesting that NMDA receptor antagonism is not the main mechanism of action of ketamine. Other receptors, such as nicotinic acetylcholine (nACh) receptors and cyclic nucleotide-gated potassium channels are other targets of ketamine that may play an important role in its anesthetic effect ().
Another receptor targeted by anesthetic agents is the γ-aminobutyric acid type A (GABAA) receptor. Several anesthetics (such as propofol, isoflurane, and halothane) are known to interact with the GABAA receptor () and potentiate its inhibitory effect. GABAA is composed of several subunits such as α, β, and γ subunits. Using knock-out mouse models lacking one of these subunits, it has been found that some anesthetics act particularly on only some of these subunits. For example, in β3 knock-out mice the immobilization effect of the anesthetics enflurane and halothane was decreased (), while the effect of isoflurane remained unchanged (). The effect on the GABAA receptor also depends on its location on the neuron. While synaptic GABAA receptors respond to fast, transient inhibitory currents in response to presynaptic GABA release, extra-synaptic GABAA receptors, located on the non-synaptic membrane, respond to low, ambient concentrations of GABA, producing a persistent inhibitory current (). Interaction with extra-synaptic GABAA receptors is thought to be responsible for the memory-related effects of anesthetic agents, since a low concentration of anesthetics can cause amnesia, but not immobilization. Moreover, anesthetics such as isoflurane and etomidate are attributed to increase cell surface expression of GABAA receptors by change in extra-synaptic GABAA receptor trafficking, effect which is associated with long-term cognitive changes ().
Altogether, evidence suggest that anesthetics act by interacting with several voltage- and ligand-gated ion channels, and the different anesthetic effects (e.g., analgesia, hypnosis, and immobility) might be mediated by different receptors. Moreover, studies of gene expression changes caused by anesthetics () might give a better insight on their mechanisms of action. The reader is referred to reviews focusing on the molecular mechanisms of action of anesthetics for a more complete insight on the topic (, , , , , ).
Effects of Anesthesia in Brain PET
The interaction of anesthetics on neuroreceptors and membrane permeability in the central and peripheral nervous system results in important physiological changes, including respiratory rate, cardiovascular function, and glucose metabolism (). For instance, pentobarbital induces respiratory depression and reduced blood pressure in rodents (). Ketamine administration causes muscle rigidity, and respiratory depression (), while ketamine/xylazine reduces heart rate (). Isoflurane depresses respiration without altering cardiac function (), and increases cerebral blood flow (). In addition, both ketamine and isoflurane induce hypothermia in small animals (, ). Changes in physiological parameters, such as cerebral blood flow and cardiac output, can in turn affect the biodistribution of PET tracers (). In a review by Alstrup and Smith () the effect of several anesthetics on the brain PET reading is summarized.
Given that receptors with which anesthetic agents interact (e.g., dopamine and GABAA receptors), can also be the target of PET ligands, anesthetics can modify the binding of these PET tracers. In this section we review several experiments that studied the effect of anesthesia on the brain PET reading of different tracers, summarizing the respective authors' hypothesis on the mechanism of interaction.
Methods to Study the Effect of Anesthesia in PET
As a first approach, the effects of anesthesia on the PET reading can be investigated by comparing PET scans performed using different anesthetics. This method allows visualization of the tracer kinetics from the onset of administration but does not reflect the awake state. To compare the state under anesthesia with the awake state, several approaches can be used: (i) Animals can be administered with the PET radiotracer in the awake state and, after some uptake period, sacrificed to perform autoradiography. Unlike dynamic PET, this method only delivers a single time point image of the radiotracer uptake in the sacrificed animal, but animals can be sacrificed at several time points to obtain pseudo-dynamic data. (ii) The animal can be administered with the radiotracer in the awake state, and following an awake uptake period (between 20 and 60 min uptake depending on the study), the animal can be anesthetized and scanned for the remainder of the uptake period. It is assumed that the effect of anesthesia is small and, if this is true, this scan reflects the awake state uptake. This approach does not allow to study the kinetics of the tracer from the onset of radiotracer administration, but pseudo-dynamic data can be obtained. (iii) The animal can be restrained during the scan and the tracer can be administered in the awake state. This method allows to perform the PET scan from the radiotracer administration onset in the awake state, but the stress caused by restraining can also affect the radiotracer uptake (e.g., due to activation/inactivation of stress related brain regions or neurotransmitters release, see section Effect of Physical Restrain in Brain PET Tomography). (iv) Using advanced methods, such as the specialized PET scanners or motion correction (described in section Small Animal Head Motion Tracking), the animal can be scanned in the awake state without physical restraining. These methods might be the optimal solution to visualize the tracer in the awake state, since no anesthesia or restrain stress is present. However, some stress might still be present by the scanning procedure itself and by restricting the animal motion to a reduced enclosure. In addition, administration of the tracer in the awake state might be challenging. Table 1 shows a summary of the studies presented in the next sections.
Table 1
| Anesthetic(s) | Method | Outcome |
|---|---|---|
| [18F]FDG (glucose metabolism) | ||
| Ketamine + xylazine, ketamine, chloral hydrate, pentobarbital, propofol, and isoflurane | Autoradiography | Decrease glucose metabolism under anesthesia compared to awake (). |
| Isoflurane | Awake uptake | Difference between saline and morphine withdrawal observed in anesthetized but not awake rats (). |
| Isoflurane, α-chloralose | Anesthetics comparison | Isoflurane: increased FDG uptake after caffeine challenge, α-chloralose: decreased FDG uptake after caffeine challenge (). |
| Isoflurane | Restrained scan | Reduced uptake and faster tracer kinetics in anesthetized compared to awake (). |
| MMB, ketamine + xylazine, chloral-hydrate, pentobarbital, propofol, and isoflurane | Restrained scan | Decreased two-tissue k3, and regional increased or decreased cerebral blood flow, in anesthetized compared to awake (). |
| Isoflurane | Awake unrestrained | Faster tracer kinetics and lower brain SUV in anesthetized compared to awake (). |
| Isoflurane | Awake unrestrained | Decaying brain FDG uptake after awake uptake period in anesthetized mice, but not in awake mice (). |
| [11C]SCH23390 (dopamine D1 receptor) | ||
| Chloral hydrate, ketamine, and pentobarbital anesthesia | Restrained scan | Higher binding potential in chloral hydrate and ketamine, lower in pentobarbital, compared to awake (). |
| [11C]raclopride (dopamine D2 receptor) | ||
| Isoflurane, fentanyl-fluanisone-midazolam | Anesthetics comparison | Doubled binding potential in isoflurane compared to fentanyl-fluanisone-midazolam (). |
| Isoflurane | Restrained scan | Lower binding potential in whole-body restrained and anesthetized mice compared to free-walking restrained (). |
| Ketamine-xylazine | Awake unrestrained | Reduced binding potential in anesthetized rats (). |
| [11C]-(+)-PHNO (dopamine D2/3 receptor) | ||
| Isoflurane | Autoradiography | Greater increase in binding potential after amphetamine challenge visible in anesthetized rats but not in awake rats (). |
| [11C]cocaine (Dopamine transporter blocker) | ||
| Isoflurane, α-chloralose | Anesthetics comparison | Clearance of [11C]cocaine from the brain was faster in isoflurane-anesthetized rats than in α-chloralose rats (). |
| [18F]FPWAY (Serotonin receptor 5-HT1A) | ||
| Isoflurane | Awake uptake | Higher distribution ratio than conscious (). |
| [18F]MK-9470 (Type 1 cannabinoid receptor) | ||
| Isoflurane and pentobarbital | Awake uptake | Higher or lower regional relative SUV compared to conscious (). |
| [18F]flumazenil (GABAA receptor) | ||
| Isoflurane, ketamine/dexmedetomidine | Awake uptake | Frontal cortex and hippocampus uptake in isoflurane and ket/dex anesthetized mice was 10 and 3-fold higher than in awake mice, respectively (). |
| [11C]-(R)-Rolipram (Phosphodiesterase subtype 4) | ||
| Isoflurane | Restrained scan | Tracer Bmax and KD significantly higher in conscious compared to anesthetized (). |
Summary of the studies investigating the effect of anesthetic agents in PET brain radiotracers.
MMB, medetomidine, midazolam, and butorphanol; Ket/dex, ketamine/dexmedetomidine.
Comparison of Different Anesthetics
Using [11C]raclopride, a dopamine D2 receptor antagonist, striatum binding potential was doubled when using fentanyl-fluanisone-midazolam compared to isoflurane anesthesia in rats scans (). Authors point out that different baseline binding potential depending on the anesthetic used might cause differing binding potential changes in challenge experiments.
The anesthetics isoflurane and α-chloralose were compared in the uptake of [11C]cocaine (dopamine transporter antagonist) in the rat brain (). This tracer was used in a cocaine challenge to study the physiological response to cocaine under different anesthetics. Using laser Doppler flowmetry and in parallel with multi-wavelength optical spectroscopy, cerebral blood flow, cerebral blood volume and tissue hemoglobin oxygenation was measured. These parameters were decreased in rats anesthetized with isoflurane compared to rats anesthetized with α-chloralose. Moreover, the clearance of [11C]cocaine from the brain was faster in isoflurane-anesthetized rats than in α-chloralose rats. Different interaction of cocaine with the anesthetics, e.g., due to increase in intracellular calcium caused by cocaine, might have caused these differences ().
Brain glucose metabolism has been investigated in a caffeine challenge, comparing the [18F]FDG uptake in isoflurane and α-chloralose anesthetized rats for different caffeine doses (). While in isoflurane anesthetized rats the highest caffeine dose significantly increased tracer uptake in several brain regions compared to baseline, the opposite effect was observed in α-chloralose anesthetized rats, i.e., lower tracer uptake than baseline at higher caffeine doses. Neurotransmitters release by caffeine administration (e.g., GABA and dopamine) and the different interaction with different anesthetics could have caused the different response ().
Awake Uptake Followed by Autoradiography
[18F]FDG uptake was compared in the conscious state and under the anesthetics ketamine + xylazine, ketamine, chloral hydrate, pentobarbital, propofol, and isoflurane (). Although ketamine did not change the overall brain [18F]FDG uptake compared to the conscious animals, it did change the brain uptake pattern, with a significant decrease uptake in the frontal cerebral cortex and a significant increase uptake in the posterior cerebral cortex. The other tested anesthetics significantly reduced the tracer uptake compared to the conscious group.
In an amphetamine challenge study, it was found that the change in tracer binding potential (compared to control rats) using the dopamine D2/3 receptor agonist [11C]-(+)-PHNO compared to the change in binding potential in the same amphetamine challenge but using [11C]raclopride, was larger using [11C]-(+)-PHNO. This increased difference in BP using [11C]-(+)-PHNO compared to [11C]raclopride was observed in isoflurane-anesthetized rats, but not in conscious rats (). This study could suggest altered dopamine levels caused by a drug/therapeutic intervention might be present in anesthetized animals but absent in clinical studies performed in conscious subjects. The authors discuss several possible mechanisms that could have caused this difference (e.g., changes in cerebral blood flow, increase dopamine release under anesthesia) but no clear hypothesis was defined.
Awake Radiotracer Uptake With Scan Under Anesthesia
Using the 5-HT1A receptor antagonist ligand [18F]FPWAY, the distribution ratio of the tracer was compared in isoflurane anesthetized and conscious rats (). Isoflurane anesthetized rats showed a significant higher hippocampus (63%) and cerebellum (32%) tracer distribution ratio than conscious rats, which the authors attribute to the decreased serotonin release in isoflurane anesthetized rats.
The influence of isoflurane and pentobarbital anesthesia on the type 1 cannabinoid receptor tracer [18F]MK-9470 has been investigated (). Although absolute standardized uptake value (SUV) was not significantly different between anesthetized and awake rats, relative SUV (to the whole brain) was significantly different between anesthetized and conscious rats in several brain regions (decrease or increase). Difference was not significant when quantified using absolute SUV values, this might have been because of the higher variability in absolute SUV values compared to normalized relative SUV values.
The GABAA receptor antagonist tracer [18F]flumazenil has been investigated under isoflurane, and ketamine/dexmedetomidine (ket/dex) anesthesia, and under the dexmedetomidine (dex) anxiolytic alone compared to awake uptake in mice (). At 25 min post-tracer injection the frontal cortex and hippocampus uptake in isoflurane and ket/dex anesthetized mice was 10 and 3-fold higher than in awake mice. In the ex-vivo analysis, the hippocampus and frontal cortex uptake were significantly higher in all anesthetized conditions compared to the awake state. Either frontal cortex or hippocampus volume of distribution (calculated from pseudo-dynamic data) was significantly different under isoflurane, ket/dex, and dex compared to the awake condition. Several effects are hypothesized to have caused these differences, such as changes in cardiac output () and cerebral blood flow due to anesthesia ().
In a morphine self-administration experiment, the effect of isoflurane anesthesia was investigated in the [18F]FDG uptake of rats that underwent withdrawal from morphine (). Following a 45 min [18F]FDG uptake either awake or under isoflurane, a 30 min PET scan under isoflurane anesthesia was acquired. A significant increase in striatum glucose metabolism in the morphine withdrawal group compared to the saline group was observed after an anesthetized tracer uptake but not after awake uptake. Authors hypothesize that higher basal glucose levels in awake animals might have hindered visualizing of changes in awake animals.
Awake Scan in Restrained Animals
The uptake of the dopamine D1 receptor ligand [11C]SCH23390 was compared in restrained conscious rats vs. the uptake in anesthetized rats using the anesthetics chloral hydrate, ketamine, and pentobarbital anesthesia (). Compared to the conscious state, the authors observed that the striatum binding potential of [11C]SCH23390 was higher using chloral hydrate and ketamine, but lower using pentobarbital. It is suggested that physiological changes (e.g., in cerebral blood flow), or blockade of the NMDA receptor by ketamine and chloral hydrate, but not pentobarbital, could have caused the difference in binding potential ().
In another study, the binding site density (Bmax) and tracer affinity (1/KD) of the phosphodiesterase subtype 4 (PDE4) tracer [11C]-(R)-Rolipram, was compared in conscious and isoflurane anesthetized rats (). Bmax and KD were determined from a saturation analysis. It was found that both Bmax and KD were significantly higher in restrained conscious rats compared to anesthetized rats. Changes in the phosphorylation status of PDE4 caused by anesthesia might have caused the differences ().
In mice, the brain uptake of [18F]FDG has been investigated in awake animals and compared to isoflurane anesthetized mice (). Brain SUV and glucose metabolic rate was significantly reduced in anesthetized mice compared to awake mice. The tracer kinetics were also modified by the use of isoflurane, indeed the [18F]FDG uptake plateau in awake mice was reached after about 30 min whereas with anesthetized mice the plateau was reached already after 2 min. The phosphorylation rate constant (k3) was reduced under anesthesia, but the glucose transport constant remained unchanged (K1).
Using a special restraining device in which the mouse head was restrained, but the extremities were allowed to move (free-walking state), scans using [11C]raclopride were compared also in whole-body restrained mice, and mice anesthetized with isoflurane (). Heart rate in free walking mice was significantly lower than whole-body restrained mice. Striatum binding potential (calculated using simplified reference tissue model with cerebellum as reference region) was significantly lower in whole-body restrained mice and isoflurane-anesthetized mice compared with restrained free-walking mice. Although both isoflurane anesthesia and restraining stress cause increment in extracellular dopamine release, authors indicate that competition is not the main cause in binding potential differences ().
Using a soft restrainer to scan rats in the awake state, [18F]FDG kinetic modeling has been performed and compared with scans under a mix of medetomidine, midazolam, and butorphanol (MMB) anesthesia, ketamine + xylazine, chloral-hydrate, pentobarbital, propofol, and isoflurane anesthesia (). Two tissue compartment K1, k2, and k4 were not significantly different between conditions, but the phosphorylation reaction constant k3 was significantly lower in all anesthetic conditions compared to the awake state. The cerebral metabolic rate of glucose was significantly higher in the conscious group compared to all anesthesia groups (Figure 1). Moreover, cerebral blood flow, measure using [125I]IMP, was not significantly different from conscious and chloral hydrate rats, but was significantly lower (compared to conscious) for MMB, ketamine + xylazine, pentobarbital, and propofol rats, and significantly higher in isoflurane anesthetized rats.
Figure 1
Awake and Unrestrained PET Scan
The RatCAP, a miniaturized PET scanner that can be surgically attached on the rat head (
Using motion tracking and motion correction reconstruction, the effect of isoflurane anesthesia in rat brain [18F]FDG uptake was investigated (
In another study using motion tracking and motion correction, [18F]FDG uptake was investigated in awake and anesthetized mice (
Effect of Physical Restrain in Brain PET Tomography
As described above, physical restrain is used to avoid the use of anesthesia. However, restraining stress itself represents a confounding factor also altering the uptake of the radiotracer. Sung et al. (
Patel et al. (
Using reverse-phase chromatography, levels of dopamine metabolites in the nucleus accumbens septi, caudate putamen, and frontal cortex were investigated in mice undergoing restraining stress for 30 and 120 min (
The uptake of [11C]-DASB, a serotonin transporter tracer, was investigated in mice exposed to chronic restraining stress (
The effect of cage transport and restraining stress was investigated in the rat brain uptake of the 5-HT1A receptor ligand [18F]MPPF (
The expression of acetylcholinesterase has also been observed to change following restrain-related stress (
All these evidence points that the brain response to restraining stress involves the reaction of many neurotransmitter systems (
Brain Pet Scans in Non-Anesthetized Unrestrained Animals to Improve Results Translation to the Clinic
From all the methods described in the previous section to study the effect of anesthetics, methods that allow scans of awake unrestrained animals resemble more closely the conditions in typical clinical PET scans. Although specialized scanners, such as the RatCAP (
Small Animal Head Motion Tracking
The motion tracking technique allows to scan awake unrestrained rodents by tracking the motion of the animal head, with any compatible tracking technology. Motion correction techniques, considering only rigid motion from the head, can then be applied to obtain motion corrected images. This method has been initially used in motion correction for clinical brain PET scans. However, motion tracking of the rodent head presents more challenges than human head motion tracking. First, the spatial resolution of preclinical scanners is usually better than in clinical scanners, with some modern systems reaching sub-millimetric resolution (
Characteristics of a Tracking System for Small Animal Brain PET
To use a tracking system for head motion correction in small animals, the system needs to meet certain criteria. The accuracy of the tracking system should be better than the spatial resolution of the PET scanner. If the position of a 3D point determined with the tracking system has an uncertainty larger than the spatial resolution of the scanner, the motion correction calculation will have the same uncertainty, therefore producing blurred images with respect to the image spatial resolution.
The tracking system additionally must have a high tracking frame rate in order to capture high-speed motion. For example, if the animal moves at a speed of 2 cm/s and a tracking frame rate of 30 frames per second is used, the animal would have moved about 0.7 mm within one frame, which is comparable with the spatial resolution of a preclinical PET scanner. Thus, an uncertainty of 0.7 mm will be present in the motion tracking data, which could translate into image blurring after motion correction. Is important to note that since most PET system perform reconstruction after data acquisition, is not necessary to perform real-time tracking, and therefore tracking processing can be performed off-line.
In order to minimally affect the animal due to the tracking procedure, the tracking method should be minimally invasive and with appropriate dimensions to fit with the PET scanner. This restricts the use of many tracking systems that use bulky systems or markers that cannot be attached to the animal head. Markerless tracking systems are therefore attractive for animal head motion tracking. These systems require no physical markers to track motion and instead can use, for example, either the natural features of the rodent head as reference points (see section Optical Motion Tracking Detecting Natural Head Features) or make use of projected structured light patterns on the animal head that help to calculate the 3D model of the head (see section Optical Motion Tracking Using Structured Light).
Ideally, the tracking system should also be able to track the motion of the animal irrespective of its position in the scanner field of view. However, many tracking systems have a limited field of measurement or the success of the tracking depends on the marker position itself. For example, for many optical tracking systems, the subject has to be facing the camera to be able to track its motion.
Finally, overall practicality is desired in order to be able to perform these types of scans on a regular basis. If the setup of the tracking system requires specialized personnel, laboratories lacking this type of personnel will not be able to perform the procedure. Moreover, if the setup of the tracking system or the time for the animal preparation is long, throughput can be compromised. Therefore, a practical tracking system is necessary to allow a wider spread of motion correction for preclinical brain PET scans. Below several tracking systems proposed for preclinical brain PET, with strengths and weaknesses in some of the requirements, are presented (Table 2).
Table 2
| Tracking method | Accuracy (mm) | Species | Frame rate (Hz) | Characteristics |
|---|---|---|---|---|
| Optical using rigid markers | 0.25 | Rats | 20–40 | Makes use of the MicronTracker camera. Markers with a checkerboard pattern are attached on the rat head ( |
| Optical using natural features | 0.2 | Rats | Up to 60 | Several cameras obtain different views of the object. Feature detected in different views are matched to calculate their 3D location ( |
| Optical using structured light | 0.33 | Rats | 30 | Makes use of the Ensenso camera. An infrared pattern projected on the object is used to calculate the object surface point cloud ( |
| PET-based point source tracking | 0.24 | Rats/mice | Up to 60 | Tracking based on the PET image. Radioactive fiducial markers are attached on the animal head, and detected in short time frames ( |
Characteristics of the different motion tracking techniques for small animal brain PET.
Optical Motion Tracking Using Rigid Markers
One of the first methods proposed to track the rat's head motion makes use of the Micron Tracker camera (Claron Technology Inc., Toronto, Canada). This camera uses stereo-vision to determine the 6 degrees of freedom (3 translation coordinates and 3 rotation angles) motion of checkerboard markers that can be printed on paper and attached to a rigid surface (Figure 2A). This camera offers sub-millimetric tracking accuracy (0.25 mm), and the markers can be made small enough to be attached to the rat head. In order to synchronize the motion tracking data with the PET data, a temporal and spatial synchronization between the tracker and the PET scanner must be performed. This camera has been adapted to the Siemens Focus 220 microPET scanner (
Figure 2

(A) Rat head motion tracking in the Siemens Inveon microPET scanner using the Micron Tracker device (
As with many optical tracking systems, the animal head must be facing the tracking camera. When the animal moves with the head opposite to the tracker, or at positions where the marker is occluded by the scanner bore, no tracking information can be acquired, and therefore the PET data during that period cannot be corrected for motion. Moreover, it might be difficult to use this marker-based camera in scanners with small bores.
This tracking system has been used together with a robotic arm in order to maximize the time the animal is inside the scanner field of view (
Optical Motion Tracking Detecting Natural Head Features
Another approach to track the animal head motion consists of detecting natural features on the animal head to determine its 6 degrees of freedom pose (
Optical Motion Tracking Using Structured Light
Combining the use of stereo vision with structured light projection the 3D surface of the animal head can be represented with point clouds (Figure 2B), which then can be used to determine the 3D pose (position and orientation) of the rat head (
PET-Based Motion Tracking Using Radioactive Point Sources
The use of radioactive fiducial markers to track the motion of the animal head has been proposed by our group (
Rigid Motion Correction Reconstruction
Once the animal head motion information has been acquired with any tracking system, the PET data can be corrected for motion. Methods devised for human head motion correction can be used in small animal motion head correction (
Event-by-event motion correction consists of repositioning every line of response (LOR) of the PET scan back to a reference pose using the motion tracking information. For brain motion correction only rigid motion/transformations are considered (
Once LORs are repositioned, they can be rebinned into sinograms, or reconstructed with list-mode reconstruction (
Due to the free motion of the animal in the scanner field of view, attenuation, and scatter correction need to be adapted for motion correction. Since the position of the animal body can have different orientations with respect to the head, the attenuation factors from the body also can change over time. An approximation to calculate the moving animal attenuation map considers the outline of the body activity as the attenuation map, with a constant attenuation factor of soft tissue (
Additional corrections can be performed to improve the image quality of the motion-corrected reconstruction. One of these corrections estimates the blurring caused by the uncertainty in the motion data to calculate a deconvolution correction in the motion-corrected image (
Novel Possibilities for Brain Behavioral Studies in Freely Moving Awake Rodents
Although one of the main motivations to perform motion correction PET scans of awake animals is to circumvent the use of anesthesia, this scanning setup also allows to perform new experimental designs not possible in anesthetized or restrained animals. In particular, quantification of the animal behavior during the PET scan has been explored using motion correction.
One of the first studies in which the animal behavior was quantified simultaneously during the PET scan was in mouse memantine challenge scans performed with the point source tracking (
Figure 3

(A) Motion histogram (top view) of a mouse PET study in a control scan and (B) motion histogram of the same mouse in a memantine challenge scan.
Using marker-based motion tracking, Kyme et al. (
Discussion
The effect of anesthesia in small animal brain PET has been demonstrated in studies performed since the early days of microPET. Since studies investigating the mechanisms of action of anesthetics demonstrate that they modify physiological parameters (e.g., respiratory rate, cerebral blood flow, etc.) and interact with neurotransmitter systems, it is expected that anesthetics will also modify the brain response to PET tracers. Tracers targeting receptors such as dopamine, serotonin, and GABAA, as well as the glucose analog [18F]FDG, have been demonstrated to be influenced by anesthetics during PET tomography.
Among the suggested mechanisms causing the difference in tracer binding due to anesthesia are the changes in physiological parameters. Changes in cerebral blood flow caused by anesthesia has been indicated as one of the possible factors producing differences in the tracer uptake compared to the awake state (
Due to the methodological differences of the studies presented, different additional confounding factors can be present, making a direct comparison of the reported results difficult. For example, studies allowing awake uptake followed by anesthesia scanning might have already an influence of anesthesia, especially for reversible tracers, depending on the pharmacokinetics of the anesthesia. In addition, stress caused by the different handling procedures, even in freely moving animal scans, can have an influence in the PET outcome. However, considering all the studies presented with different possible confounding factors, it is clear that anesthesia can influence the radiotracer uptake and kinetics in small animal brain studies.
Among the different methods used to elucidate the effect of anesthesia on the animal brain PET reading, motion tracking together with motion correction reconstruction most closely resemble the condition in the clinic, i.e., awake and unrestrained. Overall, the tracking systems presented here have good enough tracking accuracy (~0.25 mm) relative to the spatial resolution of typical preclinical scanners (1.5–1 mm). In addition, although motion correction reconstruction methods require approximations, images have comparable quality and quantitative accuracy to motion-free reconstructions.
As demonstrated in the mouse memantine (
One of the main reasons motion tracking and motion correction for brain PET scans is not widely adopted is the need for complex software, and sometimes additional hardware, to perform these procedures. Improving practicality and ease of use would allow the adoption of this technique for regular implementation in PET brain small animal scans. Therefore, additional collaboration between industry and research centers would be needed for the wider adoption and implementation of these types of scans.
Conclusions
The use of anesthesia in small animal preclinical brain PET studies represents the main confounding factor for proper translational understanding of animal models. Since clinical PET studies are usually performed without the use of anesthesia, translation of results from anesthetized animals to awake patients can also be compromised. Motion tracking with subsequent motion correction reconstruction offers the possibility to perform brain PET scans in freely moving unanesthetized animals. Several research developments have been performed in the last years, improving the accuracy and practicality of this technique, allowing the simultaneous study of animal behavior and molecular brain PET imaging. Further research and collaboration with the industry would allow wider adaptation of motion tracking and motion correction for brain PET preclinical scans.
Funding
AM was supported by the ERA-NET NEURON project SleepLess supported by BMBF (01EW1808) and FWO under the frame of Neuron Co-fund, and by a Research Project (G0A8517N) from the Research Foundation Flanders (FWO). DB was supported by the Research Foundation Flanders (FWO) through a post-doctoral fellowship (1229721N). The University of Antwerp also founded the work through a partial assistant professor position for JV and a full professor position for SSta.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
AM, DB, SStr, SSta, and JV were involved in drafting and editing the manuscript and figures. All authors approved the final manuscript and they are accountable for the content of the work.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
HessSBlombergBAZhuHJHoilund-CarlsenPFAlaviA. The pivotal role of FDG-PET/CT in modern medicine. Acad Radiol. (2014) 21:232–49. 10.1016/j.acra.2013.11.002
2.
DuclosVIepAGomezLGoldfarbLBessonFL. PET molecular imaging: a holistic review of current practice and emerging perspectives for diagnosis, therapeutic evaluation and prognosis in clinical oncology. Int J Mol Sci. (2021) 22:4159. 10.3390/ijms22084159
3.
SloughCMastersSCHurleyRATaberKH. Clinical positron emission tomography (PET) neuroimaging: advantages and limitations as a diagnostic tool. J Neuropsych Clin Neurosci. (2016) 28:66–71. 10.1176/appi.neuropsych.16030044
4.
SinghVMalhotraS. Nuclear cardiology in the literature: a selection of recent, original research papers. J Nucl Cardiol. (2020) 26:363–5. 10.1007/s12350-020-02065-9
5.
LancelotSZimmerL. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci. (2010) 31:411–7. 10.1016/j.tips.2010.06.002
6.
AlstrupAKSmithDF. Anaesthesia for positron emission tomography scanning of animal brains. Lab Anim. (2013) 47:12–8. 10.1258/la.2012.011173
7.
FranksNPLiebWR. Molecular and cellular mechanisms of general anaesthesia. Nature. (1994) 367:607–14. 10.1038/367607a0
8.
HildebrandtIJSuHWeberWA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J. (2008) 49:17–26. 10.1093/ilar.49.1.17
9.
HemmingsHCJr.RiegelhauptPMKelzMBSoltKEckenhoffRGOrserBAet al. Towards a comprehensive understanding of anesthetic mechanisms of action: a decade of discovery. Trends Pharmacol Sci. (2019) 40:464–81. 10.1016/j.tips.2019.05.001
10.
FranksNP. Molecular targets underlying general anaesthesia. Br J Pharmacol. (2006) 147(Suppl. 1):S72–81. 10.1038/sj.bjp.0706441
11.
PavelMAPetersenENWangHLernerRAHansenSB. Studies on the mechanism of general anesthesia. Proc Natl Acad Sci USA. (2020) 117:13757–66. 10.1073/pnas.2004259117
12.
DartC. Lipid microdomains and the regulation of ion channel function. J Physiol. (2010) 588(Pt 17):3169–78. 10.1113/jphysiol.2010.191585
13.
HeurteauxCGuyNLaigleCBlondeauNDupratFMazzucaMet al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. (2004) 23:2684–95. 10.1038/sj.emboj.7600234
14.
PetrenkoABYamakuraTSakimuraKBabaH. Defining the role of NMDA receptors in anesthesia: are we there yet?Eur J Pharmacol. (2014) 723:29–37. 10.1016/j.ejphar.2013.11.039
15.
RudolphUMohlerH. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol. (2004) 44:475–98. 10.1146/annurev.pharmtox.44.101802.121429
16.
RauVOhILiaoMBodarkyCFanselowMSHomanicsGEet al. Gamma-aminobutyric acid type A receptor beta3 subunit forebrain-specific knockout mice are resistant to the amnestic effect of isoflurane. Anesth Analg. (2011) 113:500–4. 10.1213/ANE.0b013e3182273aff
17.
ZurekAAYuJWangDSHaffeySCBridgwaterEMPennaAet al. Sustained increase in alpha5GABAA receptor function impairs memory after anesthesia. J Clin Invest. (2014) 124:5437–41. 10.1172/JCI76669
18.
UptonDHPopovicKFultonRKassiouM. Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brain. Sci Rep. (2020) 10:9366. 10.1038/s41598-020-66122-6
19.
WeinrichMWorcesterDL. The actions of volatile anesthetics: a new perspective. Acta Crystallogr D Struct Biol. (2018) 74(Pt 12):1169–77. 10.1107/S2059798318004771
20.
SartonETeppemaLJOlievierCNieuwenhuijsDMatthesHWKiefferBLet al. The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg. (2001) 93:1495–500. 10.1097/00000539-200112000-00031
21.
HartCYBurnettJCJr.RedfieldMM. Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol. (2001) 281:H1938–45. 10.1152/ajpheart.2001.281.5.H1938
22.
CesarovicNNichollsFRettichAKronenPHassigMJirkofPet al. Isoflurane and sevoflurane provide equally effective anaesthesia in laboratory mice. Lab Anim. (2010) 44:329–36. 10.1258/la.2010.009085
23.
MaekawaTTommasinoCShapiroHMKeifer-GoodmanJKohlenbergerRW. Local cerebral blood flow and glucose utilization during isoflurane anesthesia in the rat. Anesthesiology. (1986) 65:144–51. 10.1097/00000542-198608000-00003
24.
MurphyTJMurnaneKS. The serotonin 2C receptor agonist WAY-163909 attenuates ketamine-induced hypothermia in mice. Eur J Pharmacol. (2019) 842:255–61. 10.1016/j.ejphar.2018.11.003
25.
RufiangeMLeungVSYSimpsonKPangDSJ. Pre-warming before general anesthesia with isoflurane delays the onset of hypothermia in rats. PLoS ONE. (2020) 15:e0219722. 10.1371/journal.pone.0219722
26.
MatsumuraAMizokawaSTanakaMWadaYNozakiSNakamuraFet al. Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. Neuroimage. (2003) 20:2040–50. 10.1016/j.neuroimage.2003.08.020
27.
ParkTYNishidaKSWilsonCMJaiswalSScottJHoyARet al. Effects of isoflurane anesthesia and intravenous morphine self-administration on regional glucose metabolism ([(18) F]FDG-PET) of male Sprague-Dawley rats. Eur J Neurosci. (2017) 45:922–31. 10.1111/ejn.13542
28.
PengSLChiuHWuCYHuangCWChungYHShihCTet al. The effect of caffeine on cerebral metabolism during alpha-chloralose anesthesia differs from isoflurane anesthesia in the rat brain. Psychopharmacology. (2019) 236:1749–57. 10.1007/s00213-018-5157-4
29.
MizumaHShukuriMHayashiTWatanabeYOnoeH. Establishment of in vivo brain imaging method in conscious mice. J Nucl Med. (2010) 51:1068–75. 10.2967/jnumed.110.075184
30.
SuzukiCKosugiMMagataY. Conscious rat PET imaging with soft immobilization for quantitation of brain functions: comprehensive assessment of anesthesia effects on cerebral blood flow and metabolism. EJNMMI Res. (2021) 11:46. 10.1186/s13550-021-00787-6
31.
Spangler-BickellMGde LaatBFultonRBormansGNuytsJ. The effect of isoflurane on (18)F-FDG uptake in the rat brain: a fully conscious dynamic PET study using motion compensation. EJNMMI Res. (2016) 6:86. 10.1186/s13550-016-0242-3
32.
MirandaAGlorieDBertoglioDVleugelsJDe BruyneGStroobantsSet al. Awake (18)F-FDG PET imaging of memantine-induced brain activation and test-retest in freely running mice. J Nucl Med. (2019) 60:844–50. 10.2967/jnumed.118.218669
33.
MomosakiSHatanoKKawasumiYKatoTHosoiRKobayashiKet al. Rat-PET study without anesthesia: anesthetics modify the dopamine D-1 receptor binding in rat brain. Synapse. (2004) 54:207–13. 10.1002/syn.20083
34.
AlstrupAKOSimonsenMLandauAM. Type of anesthesia influences positron emission tomography measurements of dopamine D-2/3 receptor binding in the rat brains. Scand J Lab Anim Sci. (2011) 38:195–200. 10.23675/sjlas.v38i3.240
35.
TakuwaHMaedaJIkomaYTokunagaMWakizakaHUchidaSet al. [(11)C]Raclopride binding in the striatum of minimally restrained and free-walking awake mice in a positron emission tomography study. Synapse. (2015) 69:600–6. 10.1002/syn.21864
36.
SchulzDSouthekalSJunnarkarSSPratteJFPurschkeMLStollSPet al. Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph. Nat Methods. (2011) 8:347–52. 10.1038/nmeth.1582
37.
McCormickPNGinovartNWilsonAA. Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release. Mol Imaging Biol. (2011) 13:737–46. 10.1007/s11307-010-0380-3
38.
DuCWTullyMVolkowNDSchifferWKYuMLuoZCet al. Differential effects of anesthetics on cocaine's pharmacokinetic and pharmacodynamic effects in brain. Eur J Neurosci. (2009) 30:1565–75. 10.1111/j.1460-9568.2009.06931.x
39.
TokugawaJRavasiLNakayamaTLangLXSchmidtKCSeidelJet al. Distribution of the 5-HT1A receptor antagonist [F-18]FPWAY in blood and brain of the rat with and without isoflurane anesthesia. Eur J Nucl Med Mol Imaging. (2007) 34:259–66. 10.1007/s00259-006-0228-x
40.
CasteelsCBormansGVan LaereK. The effect of anaesthesia on [(18)F]MK-9470 binding to the type 1 cannabinoid receptor in the rat brain. Eur J Nucl Med Mol Imaging. (2010) 37:1164–73. 10.1007/s00259-010-1383-7
41.
PalnerMBeinatCBanisterSZanderigoFParkJHShenBet al. Effects of common anesthetic agents on [(18)F]flumazenil binding to the GABAA receptor. EJNMMI Res. (2016) 6:80. 10.1186/s13550-016-0235-2
42.
ItohTAbeKZoghbiSSInoueOHongJSImaizumiMet al. PET measurement of the in vivo affinity of C-11-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anesthetized rats. J Nucl Med. (2009) 50:749–56. 10.2967/jnumed.108.058305
43.
BentzenBHGrunnetM. Central and peripheral GABA(A) receptor regulation of the heart rate depends on the conscious state of the animal. Adv Pharmacol Sci. (2011) 2011:578273. 10.1155/2011/578273
44.
VaskaPWoodyCLSchlyerDJShokouhiSStollSPPratteJFet al. RatCAP: miniaturized head-mounted PET for conscious rodent brain imaging. IEEE Trans Nucl Sci. (2004) 51:2718–22. 10.1109/TNS.2004.835740
45.
SungKKJangDPLeeSKimMLeeSYKimYBet al. Neural responses in rat brain during acute immobilization stress: a [F-18]FDG micro PET imaging study. Neuroimage. (2009) 44:1074–80. 10.1016/j.neuroimage.2008.09.032
46.
LuftCGreggioSVenturinGTda CostaMSda CostaJCDonadioMVF. Sex differences in the effects of acute stress on cerebral glucose metabolism: a microPET study. Brain Res. (2019) 1722:146355. 10.1016/j.brainres.2019.146355
47.
PatelVDLeeDEAlexoffDLDeweySLSchifferWK. Imaging dopamine release with Positron Emission Tomography (PET) and (11)C-raclopride in freely moving animals. Neuroimage. (2008) 41:1051–66. 10.1016/j.neuroimage.2008.02.065
48.
CabibSKempfESchleefCOliverioAPuglisi-AllegraS. Effects of immobilization stress on dopamine and its metabolites in different brain areas of the mouse: role of genotype and stress duration. Brain Res. (1988) 441:153–60. 10.1016/0006-8993(88)91393-5
49.
BurokasAMartin-GarciaEGutierrez-CuestaJRojasSHeranceJRGispertJDet al. Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [11C]-DASB. J Neurochem. (2014) 130:126–35. 10.1111/jnc.12716
50.
BucheckerVWaldronAMvan DijkRMKoskaIBrendelMvonUngern-Sternberg Bet al. [(18)F]MPPF and [(18)F]FDG muPET imaging in rats: impact of transport and restraint stress. EJNMMI Res. (2020) 10:112. 10.1186/s13550-020-00693-3
51.
DasAKapoorKSayeepriyadarshiniATDikshitMPalitGNathC. Immobilization stress-induced changes in brain acetylcholinesterase activity and cognitive function in mice. Pharmacol Res. (2000) 42:213–7. 10.1006/phrs.2000.0678
52.
KonstandiMJohnsonELangMAMalamasMMarselosM. Noradrenaline, dopamine, serotonin: different effects of psychological stress on brain biogenic amines in mice and rats. Pharmacol Res. (2000) 41:341–6. 10.1006/phrs.1999.0597
53.
DeleyeSVerhaegheJWyffelsLDedeurwaerdereSStroobantsSStaelensS. Towards a reproducible protocol for repetitive and semi-quantitative rat brain imaging with (18) F-FDG: exemplified in a memantine pharmacological challenge. Neuroimage. (2014) 96:276–87. 10.1016/j.neuroimage.2014.04.004
54.
AmirrashediMZaidiHAyMR. Advances in preclinical PET instrumentation. Pet Clin. (2020) 15:403–26. 10.1016/j.cpet.2020.06.003
55.
PicardYThompsonCJ. Motion correction of PET images using multiple acquisition frames. IEEE Trans Med Imaging. (1997) 16:137–44. 10.1109/42.563659
56.
Spangler-BickellMGZhouLKymeAZDe LaatBFultonRRNuytsJ. Optimising rigid motion compensation for small animal brain PET imaging. Phys Med Biol. (2016) 61:7074–91. 10.1088/0031-9155/61/19/7074
57.
KymeASeSMeikleSAngelisGRyderWPopovicKet al. Markerless motion tracking of awake animals in positron emission tomography. IEEE Trans Med Imaging. (2014) 33:2180–90. 10.1109/TMI.2014.2332821
58.
MirandaAStaelensSStroobantsSVerhaegheJ. Markerless rat head motion tracking using structured light for brain PET imaging of unrestrained awake small animals. Phys Med Biol. (2017) 62:1744–58. 10.1088/1361-6560/aa5a46
59.
MirandaAStaelensSStroobantsSVerhaegheJ. Fast and accurate rat head motion tracking with point sources for awake brain PET. IEEE Trans Med Imaging. (2017) 36:1573–82. 10.1109/TMI.2017.2667889
60.
MirandaAStaelensSStroobantsSVerhaegheJ. Estimation of and correction for finite motion sampling errors in small animal PET rigid motion correction. Med Biol Eng Comput. (2019) 57:505–18. 10.1007/s11517-018-1899-8
61.
MirandaAKangMSBlinderSBouhachiRSoucyJPAliaga-AliagaAet al. PET imaging of freely moving interacting rats. Neuroimage. (2019) 191:560–7. 10.1016/j.neuroimage.2019.02.064
62.
KymeAZZhouVWMeikleSRFultonRR. Real-time 3D motion tracking for small animal brain PET. Phys Med Biol. (2008) 53:2651–66. 10.1088/0031-9155/53/10/014
63.
ZhouVEisenhuthJKymeAAkhtarMFultonRMeikleS. A motion adaptive animal chamber for PET imaging of freely moving animals. IEEE Trans Nucl Sci. (2013) 60:3423–31. 10.1109/TNS.2013.2277857
64.
KymeAZAngelisGIEisenhuthJFultonRRZhouVHartGet al. Open-field PET: simultaneous brain functional imaging and behavioural response measurements in freely moving small animals. Neuroimage. (2019) 188:92–101. 10.1016/j.neuroimage.2018.11.051
65.
BayHEssATuytelaarsTVan GoolL. Speeded-up robust features (SURF). Comput Vis Image Und. (2008) 110:346–59. 10.1016/j.cviu.2007.09.014
66.
ChetverikovDStepanovDKrsekP. Robust Euclidean alignment of 3D point sets: the trimmed iterative closest point algorithm. Image Vision Comput. (2005) 23:299–309. 10.1016/j.imavis.2004.05.007
67.
KymeAZFultonRR. Motion estimation and correction in SPECT, PET and CT. Phys Med Biol. (2021) 66. 10.1088/1361-6560/ac093b
68.
RahmimADinelleKChengJCShilovMASegarsWPLidstoneSCet al. Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. IEEE Trans Med Imaging. (2008) 27:1018–33. 10.1109/TMI.2008.917248
69.
ChanCOnofreyJJianYGerminoMPapademetrisXCarsonREet al. Non-rigid event-by-event continuous respiratory motion compensated list-mode reconstruction for PET. IEEE Trans Med Imaging. (2018) 37:504–15. 10.1109/TMI.2017.2761756
70.
VardiYSheppLAKaufmanL. A statistical-model for positron emission tomography. J Am Stat Assoc. (1985) 80:8–20. 10.1080/01621459.1985.10477119
71.
ZhouVWKymeAZMeikleSRFultonR. A scheme for PET data normalization in event-based motion correction. Phys Med Biol. (2009) 54:5321–39. 10.1088/0031-9155/54/17/016
72.
CarsonREBarkerWCLiowJSJohnsonCA. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. IEEE Nucl Sci Conf Rec. (2004) 5:3281–5. 10.1109/NSSMIC.2003.1352597
73.
AngelisGBickellMKymeARyderWZhouLNuytsLet al. Calculated attenuation correction for awake small animal brain PET studies 2013. In: IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC)Seoul, South Korea (2013).
74.
AngelisGIKymeAZRyderWJFultonRRMeikleSR. Attenuation correction for freely moving small animal brain PET studies based on a virtual scanner geometry. Phys Med Biol. (2014) 59:5651–66. 10.1088/0031-9155/59/19/5651
75.
AngelisGGillamJEKymeAZFultonRRMeikleSR. Image-based modelling of residual blurring in motion corrected small animal PET imaging using motion dependent point spread functions. Biomed Phys Eng Expr. (2018) 4. 10.1088/2057-1976/aab922
76.
MirandaAStaelensSStroobantsSVerhaegheJ. Motion dependent and spatially variant resolution modeling for PET rigid motion correction. IEEE Trans Med Imaging. (2020) 39:2518–30. 10.1109/TMI.2019.2962237
77.
DuboisAHerardASFlandinGDuchesnayEBesretLFrouinVet al. Quantitative validation of voxel-wise statistical analyses of autoradiographic rat brain volumes: application to unilateral visual stimulation. Neuroimage. (2008) 40:482–94. 10.1016/j.neuroimage.2007.11.054
78.
YuanTFSlotnickBM. Roles of olfactory system dysfunction in depression. Prog Neuropsychopharmacol Biol Psychiatry. (2014) 54:26–30. 10.1016/j.pnpbp.2014.05.013
79.
MoraesMMRabeloPCRPintoVAPiresWWannerSPSzawkaREet al. Auditory stimulation by exposure to melodic music increases dopamine and serotonin activities in rat forebrain areas linked to reward and motor control. Neurosci Lett. (2018) 673:73–8. 10.1016/j.neulet.2018.02.058
Summary
Keywords
positron emission tomography, preclinical, brain, anesthesia, motion correction
Citation
Miranda A, Bertoglio D, Stroobants S, Staelens S and Verhaeghe J (2021) Translation of Preclinical PET Imaging Findings: Challenges and Motion Correction to Overcome the Confounding Effect of Anesthetics. Front. Med. 8:753977. doi: 10.3389/fmed.2021.753977
Received
05 August 2021
Accepted
27 September 2021
Published
22 October 2021
Volume
8 - 2021
Edited by
Adriana Tavares, University of Edinburgh, United Kingdom
Reviewed by
Takuya Toyonaga, Yale University, United States; Kritika Subramanian, Weill Cornell Medicine, United States
Updates

Check for updates
Copyright
© 2021 Miranda, Bertoglio, Stroobants, Staelens and Verhaeghe.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jeroen Verhaeghe jeroen.verhaeghe@uantwerpen.be
This article was submitted to Nuclear Medicine, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.